Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 25 Triple Negative Breast Neoplasms 12 Prostatic Neoplasms 11 Ovarian Neoplasms 10 Neoplasms 8 Neoplasm Metastasis 8 Leukemia, Myeloid, Acute 5 Fallopian Tube Neoplasms 5 Small Cell Lung Carcinoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Pancreatic Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

Temozolomide 140 Bevacizumab 63 Radiotherapy 54 Magnetic Resonance Spectroscopy 52 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 18 Radiation 18 Carmustine 18 Specimen Handling 17 Nivolumab 16 Lomustine 15 Biopsy 15 Aminolevulinic Acid 15 pembrolizumab 12 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 9 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 X-Rays 8 Imatinib Mesylate 8 Filgrastim 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡